513 assets in Ovarian Cancer

Therapeutic assets addressing Ovarian Cancer, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Nms-03305293 Ovarian Cancer	Nerviano Medical Sciences	P1	C (36)
Nrm-823 Ovarian Cancer	Normunity AccelCo, Inc.	P1	C (36)
Nuv-868 Ovarian Cancer	Nuvation Bio Inc.	P1	C (36)
nxp800 Ovarian Cancer	Nuvectis Pharma, Inc.	P1	C (36)
Obinutuzumab Ovarian Cancer	NeoTX Therapeutics Ltd.	P1	C (36)
Opb-201 Ovarian Cancer	Outpace Bio, Inc.	P1	C (36)
Ovm-200 Ovarian Cancer	Oxford Vacmedix UK Ltd.	P1	C (36)
Pcna Inhibitor Aoh1996 Ovarian Cancer	City of Hope Medical Center	P1	C (36)
pf-07224826 Ovarian Cancer	Pfizer	P1	C (36)
pf-07263689 Ovarian Cancer	Pfizer	P1	C (36)
Phn-010 Ovarian Cancer	Pheon Therapeutics	P1	C (36)
Phst001 Ovarian Cancer	Pheast Therapeutics	P1	C (36)
Pittsburgh Compound B Unlabelled Ovarian Cancer	University of Alabama at Birmingham	P1	C (36)
P-Muc1C-Allo1 Car-T Cells Ovarian Cancer	Poseida Therapeutics, Inc.	P1	C (36)
QXL138AM Ovarian Cancer	Nammi Therapeutics Inc	P1	C (36)
rad301 Ovarian Cancer	Radiopharm Theranostics, Ltd	P1	C (36)
Rgt-490 Ovarian Cancer	Regor Pharmaceuticals Inc.	P1	C (36)
Rimiducid Ovarian Cancer	Poseida Therapeutics, Inc.	P1	C (36)
Sct-001 Car-T Cells Ovarian Cancer	Shanghai Gynecologic Oncology Group	P1	C (36)
Slv-154 Ovarian Cancer	Solve Therapeutics	P1	C (36)
Son-Dp Ovarian Cancer	Qurgen Inc.	P1	C (36)
syn608 Ovarian Cancer	Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd	P1	C (36)
syn818 Ovarian Cancer	Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd	P1	C (36)
Synkir-110, Autologous T Cells Transduced With Mesothelin Kir-Car Ovarian Cancer	Verismo Therapeutics	P1	C (36)
sys6043 Ovarian Cancer	Conjupro Biotherapeutics, Inc.	P1	C (36)
Tbi-1301 Ovarian Cancer	University Health Network, Toronto	P1	C (36)
Teonanacatl Ovarian Cancer	University of Colorado, Denver	P1	C (36)
Tsc-200-A0201 Ovarian Cancer	TScan Therapeutics, Inc.	P1	C (36)
Tsc-201-B0702 Ovarian Cancer	TScan Therapeutics, Inc.	P1	C (36)
Tsc-202-A0201 Ovarian Cancer	TScan Therapeutics, Inc.	P1	C (36)
Tsc-203-A0201 Ovarian Cancer	TScan Therapeutics, Inc.	P1	C (36)
Tsc-204-A0101 Ovarian Cancer	TScan Therapeutics, Inc.	P1	C (36)
Tsc-204-A0201 Ovarian Cancer	TScan Therapeutics, Inc.	P1	C (36)
Tsc-204-C0702 Ovarian Cancer	TScan Therapeutics, Inc.	P1	C (36)
Vudalimab Ovarian Cancer	Xencor, Inc.	P2	C (36)
Xmab541 Ovarian Cancer	Xencor, Inc.	P1	C (36)
Xmab808 Ovarian Cancer	Xencor, Inc.	P1	C (36)
Zi-Ma4-1 Ovarian Cancer	Zelluna Immunotherapy AS	P1	C (36)
1-118-Signal regulatory protein ? (human) fusion protein with immunoglobulin G4 [128-proline] (human ?4-chain C region C-terminal fragment), dimer Ovarian Cancer	Pfizer	P1/2	C (35)
Alpha-Type-1 Polarized Dendritic Cells Ovarian Cancer	Roswell Park Cancer Institute	P1/2	C (34)
kt032 Ovarian Cancer	Weijia Fang, MD	Early P1	C (33)
Montelukast Ovarian Cancer	University of South Florida	Early P1	C (33)
nk521 cell Ovarian Cancer	Base Therapeutics (Shanghai) Co., Ltd.	Early P1	C (33)
R130 Ovarian Cancer	Shanghai Yunying Medical Technology	Early P1	C (33)
Capsulex Ovarian Cancer	The First Hospital of Jilin University	N/A	D (30)
frd001 Ovarian Cancer	Tongji Hospital	N/A	D (30)
Sasanlimab Ovarian Cancer	Pfizer	P1	D (27)
Huaier Granule Ovarian Cancer	Ruijin Hospital	N/A	D (26)
Jnj-54135419 Ovarian Cancer	Zhejiang Cancer Hospital	N/A	D (26)

Showing 451 to 500 of 513 assets

PreviousPage 10 of 11Next